Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.
MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.
Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.
All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.
MediPharm Labs Corp. (OTCQX: MEDIF) has announced the launch of its partnership with STADA Arzneimittel AG in Germany, allowing patients to access GMP-certified medical cannabis products through local pharmacies under the CannabiSTADA brand. The agreement, effective April 2021, includes the supply of eight differentiated products targeting chronic pain management. With an estimated market growth from €150m to €1.5bn by 2025 in Germany, this collaboration marks MediPharm Labs' entry into the European pharmaceutical market. STADA aims to enhance medical education and patient access to these products.
MediPharm Labs (OTCQX: MEDIF) reported its financial results for Q4 and FY 2020, showing a sequential revenue increase of 22% to $6.1 million. Total annual revenue reached $36 million. The company achieved significant cost reductions, totaling over $3.6 million annually, while cash reserves stood at $19.9 million after repaying debts. Despite progress, the company incurred a Q4 net loss before tax of $30.9 million. They have established over 30 international agreements and received a Cannabis Drug License from Health Canada, indicating strong growth in the pharmaceutical cannabis sector.
MediPharm Labs Corp. (OTCQX: MEDIF) will release its fourth-quarter financial results on March 31, 2021. The announcement covers results for the three and twelve months ended December 31, 2020. An audio conference call and webcast are scheduled for the same day at 8:30 a.m. ET to discuss these results and the company's outlook. MediPharm Labs specializes in pharmaceutical-quality cannabis extraction and has invested in advanced technologies and facilities. The company has a fully operational Australian extraction facility and continues to expand its market reach.
MediPharm Labs Corp. (OTCQX: MEDIF) has secured its seventh provincial distribution agreement in Quebec, enhancing its reach to over 95% of the Canadian retail market. This agreement with the Société Quebecois Du Cannabis enables the company to supply cannabis concentrate products in the province's medical and wellness sector. MediPharm's products will be available through SQDC's retail stores and online platform. Currently, it distributes in six other provinces, aiming for further expansion in 2021.
MediPharm Labs Corp. (OTCQX: MEDIF) has entered a three-year GMP white-label supply and manufacturing agreement with Cannim Australia Pty Ltd. This agreement will see the supply of specially formulated CBD and THC products under Cannim’s Lumir brand. In addition, MediPharm is launching next-generation OTC CBD products in Australia, following regulatory changes allowing low dosage CBD sales without prescriptions. The Therapeutic Goods Administration (TGA) reclassified CBD in February 2021, paving the way for enhanced market opportunities.
MediPharm Labs Corp. (OTCQX: MEDIF) announced a bought deal financing agreement with Cantor Fitzgerald Canada Corp. to sell 34.5 million units at $0.58 each, totaling $20.01 million. Each unit consists of one common share and a warrant to purchase an additional share at $0.70 for two years. The offering, slated to close around March 5, 2021, includes an option for underwriters to purchase 5.175 million additional units. Proceeds will fund growth in product portfolios, clinical research, and working capital.
MediPharm Labs Corp. (OTCQX: MEDIF) has received a Cannabis Drug Licence (CDL) from Health Canada, critical for manufacturing cannabis-based prescription drugs. This licence enhances MediPharm's ability to work with existing pharmaceutical customers and to collaborate with new pharma companies for drug development and clinical trials. Established in 2015, MediPharm specializes in high-quality cannabis extraction and has invested in certified facilities and technology. The CDL licence positions the company favorably within the pharmaceutical industry supply chain.
MediPharm Labs Corp. announced the appointment of Greg Hunter as Chief Financial Officer (CFO), effective February 8, 2021. Hunter brings over 20 years of experience in finance and leadership roles across various industries, including pharmaceuticals and healthcare. His previous role was CFO at Medical Pharmacies Group, and he has held senior positions at Baxter International Inc. and Janssen-Ortho Inc. The company is optimistic about Hunter's expertise in capital management and strategic growth, which aligns with its goal of expanding its pharmaceutical operations.
MediPharm Labs Corp (OTCQX: MEDIF) has initiated a clinical trial to evaluate its cannabis-derived medical products for treating Chronic Kidney Disease (CKD), which affects approximately 37 million adults in the U.S. MediPharm's partnership with OTT Healthcare Inc. aims to study the safety and efficacy of its formulations. This trial marks a significant step toward providing evidence-based medical cannabis benefits to CKD patients, addressing severe symptoms and improving their quality of life.
The partnership between STADA and MediPharm marks a significant milestone in the global cannabis industry, particularly in medical cannabis commercialization. As a large pharmaceutical entity, STADA will leverage MediPharm’s GMP-certified cannabis production to tap into Germany's burgeoning medical cannabis market, projected to reach €1.5 billion by 2025. MediPharm will supply cannabis products, while STADA will handle marketing and distribution, aiming for substantial revenue growth. This collaboration positions both companies strategically within the European pharmaceutical landscape.
